Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants (IMAGE)

La Jolla Institute for Immunology

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants

Caption

T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

Credit

La Jolla Institute for Immunology

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.